The studies using NRG mice for CTCL research found that the combined use of chlorpromazine and romidepsin displayed significant antitumor activity (Cortes et al., 2021), and the expression of CD38 is associated with the progression of CTCL, suggesting that CD38 could potentially become a new target for therapeutic intervention (Isabelle et al., 2022). The gene discussed is CD38; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.